Secondary endpoints of efficacy (patient and physician global assessments and a quality of life assessment) also supported the use of ipratropium bromide nasal spray for rhinitis symptom control.

The USFDA approved company’s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 ... Bromide Nasal Solution id use for the symptomatic relief ...

Grasim Industries, the flagship entity of the Aditya Birla Group, posted a consolidated net loss of ₹ 168.7 crore for Q3 FY25 ...

The Indian stock market is set for an eventful session today, with Gift Nifty opening at 23,485.5 and currently trading 0.06% ...

Due to the risk of rebound congestion (known by some as rhinitis medicamentosa or nasal spray addiction), over-the-counter decongestant ... Binder E. Ipratropium (Atrovent) in the treatment of ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...

Lupin has received approval from the Food and Drug Administration for ipratropium bromide nasal solution (nasal spray), 0.06%, which is a generic of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%.